Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.
The insulin-like growth factor (IGF) axis is associated intimately with prostate cancer (PCa) development, growth, survival and metastasis. In particular, increased levels of IGFBP-2 expression are associated with advanced PCa, bone metastasis, and the development of castrate resistant PCa. Previously, we reported that androgen treatment decreased intracellular and extracellular IGFBP-2 in the androgen sensitive (AS) PCa cell line, LNCaP. Nonetheless, the mechanism by which androgen treatment decreases expression of IGFBP-2 is not clear. Since elevated IGFBP-2 is associated with a variety of advanced cancers, including PCa, coupled with the fact that hormone ablation is the customary treatment modality for advanced PCa, a complete understanding of the influence of androgens on IGFBP-2 expression is essential. Androgen treatment initially increased steady state IGFBP-2 mRNA levels in LNCaP cells. Extended androgen treatment on LNCaP resulted in a time-dependent decrease in both steady state IGFBP-2 mRNA and protein. Polysomal mRNA analysis showed no difference in IGFBP-2 association with a given fraction; however, Q-PCR revealed less IGFBP-2 mRNA in each androgen-treated fraction. In addition, there was an overall decrease in polysome mRNA after androgen treatment. Extracellular proteolysis of IGFBP-2 was prevented in the presence of serine protease inhibitors. These data indicate that androgen acts via multiple levels to down-regulate IGFBP-2 in LNCaP PCa cells.
Degraff
David J
DJ
Aguiar
Adam A
AA
Chen
Qian
Q
Adams
Lisa K
LK
Williams
B Jill
BJ
Sikes
Robert A
RA
Endocr Rev. 2007 Feb;28(1):20-47
16931767
Am J Transl Res. 2009 Jan 20;1(2):115-30
19956425
Eur Urol. 2005 May;47(5):695-702
15826765
Prostate. 2006 Jun 1;66(8):789-800
16482567
Biol Reprod. 1999 Sep;61(3):687-91
10456846
Endocr Rev. 2002 Dec;23(6):824-54
12466191
Cochrane Database Syst Rev. 2000;(2):CD001526
10796804
Mol Endocrinol. 1992 May;6(5):826-36
1376411
Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2)
10881018
Cancer Lett. 2006 Dec 8;244(2):274-88
16500022
Endocrinology. 1989 Nov;125(5):2719-27
2792005
Urologe A. 2009 Feb;48(2):183-8; quiz 189-90
19214617
Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E573-84
15536203
Prostate. 2003 Mar 1;54(4):249-57
12539223
Mol Cell Endocrinol. 1999 Sep 10;155(1-2):9-18
10580834
Clin Invest Med. 1993 Dec;16(6):532-8
8013157
Prostate. 2004 Dec 1;61(4):332-53
15389811
Novartis Found Symp. 2004;262:84-98; discussion 98-107, 265-8
15562824
Ann N Y Acad Sci. 2003 Dec;1002:95-104
14751827
Prog Clin Biol Res. 1980;37:115-32
7384082
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:47-57
16273354
J Cell Physiol. 2007 Oct;213(1):261-8
17492783
Nat Rev Cancer. 2002 May;2(5):389-96
12044015
Int J Cancer. 2003 May 20;105(1):14-9
12672024
Cancer Res. 2003 Jul 1;63(13):3575-84
12839944
Endocrinology. 2000 Jul;141(7):2401-9
10875240
Prostate. 2004 Jan 1;58(1):41-9
14673951